MiniMed Group, Inc. (MMED) Stock Analysis and Metrics

MiniMed

NASDAQ: MMED

$16.83 ▲ +0.50 (+3.06%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap4.19 Bn

P/E-8.88

P/S1.38

Div. Yield0.05

Revenue Growth (1y) (Qtr)15.61

Add ratio to table…

About

MiniMed Group, Inc. is a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Founded more than 40 years ago, the company has pioneered groundbreaking innovations in diabetes care, evolving from early insulin pumps to today's advanced automated insulin delivery systems, all in service of its mission to make every day better for people with diabetes. Today, MiniMed is the sole provider offering a fully integrated system that encompasses all components of diabetes management technology, including insulin delivery devices, continuous glucose monitors, dosing algorithms, and connected software platforms, enabling seamless therapy management for patients worldwide. The company's portfolio features second generation automated insulin delivery systems like the MiniMed 780G, which combines pump technology with real-time glucose sensing and automated dosing, alongside smart multiple daily injection solutions that enhance manual insulin therapy through connected devices and software.

MiniMed Group, Inc. generates revenue through the sale of diabetes management products and services. In the six months ended October 24, 2025 and fiscal year 2025, the company reported revenue of $1.5 billion and $2.7 billion, respectively. Its primary offerings consist of insulin delivery devices such as insulin pumps and smart pens, continuous glucose monitors (CGMs), consumables including infusion sets and reservoirs, and associated software, data analytics, and support services. The company serves individuals requiring intensive insulin therapy, which includes all people with type 1 diabetes and a subset of those with type 2 diabetes who need basal and bolus insulin. Revenue is generated via direct-to-consumer channels and healthcare provider partnerships, with U. S. products primarily distributed through the durable medical equipment (DME) channel and a smaller percentage through the pharmacy channel. Device sales, primarily insulin pumps and pens, contributed approximately 17% and 20% of revenue in the six months ended October 2025 and fiscal year 2025, respectively, while recurring sales of CGMs, consumables, and digital solutions accounted for the remaining 83% and 80%, underscoring the durability of the company's revenue stream from ongoing customer engagement with its ecosystem of products and services.

MiniMed Group, Inc. holds a dominant position in the diabetes technology market. It is recognized as the global leader in insulin pump users, serving more than 640,000 patients across approximately 80 countries based on Seagrove Partners' November 2025 GlobeVIEW Scoreboard. Key competitors in the insulin pump space include Insulet operating in 16 countries, Tandem in 23 countries, Ypsomed in 16 countries, and Beta Bionics in one country, demonstrating MiniMed's significantly broader international footprint. The company operates in a substantial and growing market, with the total addressable opportunity for diabetes technologies exceeding $18 billion based on the last twelve months ended September 2025 revenue from leading competitors, and projected to expand at a compound annual growth rate above 10% through 2030 according to Seagrove Partners' November 2025 market model. MiniMed's competitive advantages arise from its vertically integrated business model, as it is the only firm that designs manufactures and commercializes all elements of an integrated diabetes management system. This integration ensures superior product compatibility a cohesive user experience and enhanced capabilities for refining dosing algorithms through combined device data. Additional strengths include an extensive intellectual property portfolio with over 2,500 patents and patent applications worldwide as of October 2025, robust clinical evidence from over 200 peer-reviewed publications, eight randomized controlled trials, and nine health economic analyses supporting the efficacy of its systems, a scalable manufacturing infrastructure with over five million insulin pumps produced since 2001 providing operational leverage, and substantial investment in innovation, with $236 million allocated to research and development in the six months ended October 2025 and $1.3 billion over the last three fiscal years. Furthermore, MiniMed benefits from strong international revenue, with outside-U. S. sales representing 70% and 67% of total revenue in the six months ended October 2025 and fiscal year 2025, respectively, reflecting its established global commercial presence and leadership in key regions such as Australia, Benelux, France, Germany, Israel, Italy, the Scandinavian region, and Spain.

MiniMed Group, Inc. serves individuals with diabetes who require intensive insulin therapy, encompassing all people with type 1 diabetes and a subset of those with type 2 diabetes who need basal and bolus insulin for glucose management. The company also supports caregivers and healthcare professionals involved in the daily management of diabetes. Its commercial relationships extend to over 40,000 prescribing healthcare providers globally, primarily consisting of endocrinologists, diabetologists, nurse practitioners, physician assistants, and primary care physicians who recommend and oversee the use of its products for patient care. As of October 2025, MiniMed reported more than 640,000 users of its flagship MiniMed 780G automated insulin delivery system across approximately 80 countries, illustrating its extensive global patient base. The company's offerings are utilized by a diverse demographic of patients spanning various age groups, from pediatric to adult populations, and various socioeconomic backgrounds who depend on its technology for effective diabetes management, improved glycemic control, and enhanced quality of life.

Investment Thesis

▲ Bull case

MiniMed's recent FDA clearance of the MiniMed Flex™ system represents a transformative leap in insulin delivery technology that the market is significantly undervaluing, as its discreet screenless design and smartphone-controlled interface directly address the unspoken pain point of device burden and stigma, particularly among younger users and active adults who prioritize seamless integration into daily life; this is reinforced by the MiniMed Forward Program offering zero-cost upgrades from the established 780G base, which creates a powerful installed-base migration pathway that could accelerate adoption beyond current pump replacement cycles, and while management highlighted the product's size and algorithm, they understated the strategic implication of Abbott's Instinct sensor compatibility—which, per the randomized crossover trial data showing nearly identical Time-in-Range outcomes (79.1% vs 80.6%) between Abbott and Medtronic sensors—de-risks supply chain dependencies and opens the door to broader sensor ecosystem flexibility, a hidden catalyst that could drive gross margin expansion as MiniMed leverages Abbott's scale for sensor procurement while retaining control over its high-value algorithm and app ecosystem, positioning the company to capture share in the growing discrete wearable market without the R&D burden of developing proprietary sensors.
The company's international revenue growth of 22.4% in Q4 FY26 and 20.6% for the full year, even after adjusting for currency and Italian payback accruals, reveals a structural shift in global diabetes care adoption that management did not emphasize enough during the earnings call, particularly in emerging markets where universal healthcare systems are increasingly reimbursing advanced hybrid closed-loop (AHCL) systems like the 780G and Flex™ as cost-effective long-term solutions to reduce complications; this is underscored by the real-world study showing 76.3% Time-in-Range on missed bolus days with optimal settings—a figure that exceeds ADA targets and demonstrates the algorithm's robustness in real-world adherence gaps—yet MiniMed framed this as a labeling compliance issue rather than a testament to the system's ability to mitigate human error, which is a critical, underappreciated differentiator in markets with limited endocrinologist access where automated correction is not just convenient but clinically necessary, and with operations in over 80 countries, the company is uniquely positioned to benefit from WHO's global diabetes compact targets aiming for 80% diagnosis and treatment coverage by 2030, a secular tailwind not priced into the current valuation.
MiniMed's expanded partnership with Abbott to develop dual glucose-ketone sensors represents a quiet but potentially paradigm-shifting advancement in diabetes safety that the market is overlooking, as continuous ketone monitoring could prevent diabetic ketoacidosis (DKA)—the leading cause of death in type 1 diabetes under age 58—by enabling pre-symptomatic intervention, a feature that transforms the insulin delivery system from a glucose-management tool into a comprehensive metabolic safety net; while Abbott's sensors remain under FDA review, the CE Mark in Europe and the explicit design integration with MiniMed's smart dosing systems suggest a near-term commercialization path that could justify premium pricing or reimbursement bonuses, especially in value-based care models penalizing DKA admissions, and management's focus on "peace of mind" undersells the economic upside: preventing even a fraction of the hundreds of thousands of annual U.S. DKA hospitalizations could generate significant offset savings for payers, creating a strong incentive for coverage adoption that MiniMed has not yet quantified in its guidance but which could drive accelerated uptake of its AID systems as the standard of care for high-risk patients, a catalyst that remains unpriced in the current stock valuation.

MiniMed's recent FDA clearance of the MiniMed Flex™ system represents a transformative leap in insulin delivery technology that the market is significantly undervaluing, as its discreet screenless design and smartphone-controlled interface directly address the unspoken pain point of device burden and stigma, particularly among younger users and active adults who prioritize seamless integration into daily life; this is reinforced by the MiniMed Forward Program offering zero-cost upgrades from the established 780G base, which creates a powerful installed-base migration pathway that could accelerate adoption beyond current pump replacement cycles, and while management highlighted the product's size and algorithm, they understated the strategic implication of Abbott's Instinct sensor compatibility—which, per the randomized crossover trial data showing nearly identical Time-in-Range outcomes (79.1% vs 80.6%) between Abbott and Medtronic sensors—de-risks supply chain dependencies and opens the door to broader sensor ecosystem flexibility, a hidden catalyst that could drive gross margin expansion as MiniMed leverages Abbott's scale for sensor procurement while retaining control over its high-value algorithm and app ecosystem, positioning the company to capture share in the growing discrete wearable market without the R&D burden of developing proprietary sensors.
The company's international revenue growth of 22.4% in Q4 FY26 and 20.6% for the full year, even after adjusting for currency and Italian payback accruals, reveals a structural shift in global diabetes care adoption that management did not emphasize enough during the earnings call, particularly in emerging markets where universal healthcare systems are increasingly reimbursing advanced hybrid closed-loop (AHCL) systems like the 780G and Flex™ as cost-effective long-term solutions to reduce complications; this is underscored by the real-world study showing 76.3% Time-in-Range on missed bolus days with optimal settings—a figure that exceeds ADA targets and demonstrates the algorithm's robustness in real-world adherence gaps—yet MiniMed framed this as a labeling compliance issue rather than a testament to the system's ability to mitigate human error, which is a critical, underappreciated differentiator in markets with limited endocrinologist access where automated correction is not just convenient but clinically necessary, and with operations in over 80 countries, the company is uniquely positioned to benefit from WHO's global diabetes compact targets aiming for 80% diagnosis and treatment coverage by 2030, a secular tailwind not priced into the current valuation.
MiniMed's expanded partnership with Abbott to develop dual glucose-ketone sensors represents a quiet but potentially paradigm-shifting advancement in diabetes safety that the market is overlooking, as continuous ketone monitoring could prevent diabetic ketoacidosis (DKA)—the leading cause of death in type 1 diabetes under age 58—by enabling pre-symptomatic intervention, a feature that transforms the insulin delivery system from a glucose-management tool into a comprehensive metabolic safety net; while Abbott's sensors remain under FDA review, the CE Mark in Europe and the explicit design integration with MiniMed's smart dosing systems suggest a near-term commercialization path that could justify premium pricing or reimbursement bonuses, especially in value-based care models penalizing DKA admissions, and management's focus on "peace of mind" undersells the economic upside: preventing even a fraction of the hundreds of thousands of annual U.S. DKA hospitalizations could generate significant offset savings for payers, creating a strong incentive for coverage adoption that MiniMed has not yet quantified in its guidance but which could drive accelerated uptake of its AID systems as the standard of care for high-risk patients, a catalyst that remains unpriced in the current stock valuation.

▼ Bear case

Despite the positive top-line growth, MiniMed's fundamental profitability challenges are being underestimated by the market, as the company reported a net loss of $331 million for FY26—worsening from $213 million in FY25—driven not just by transient costs but by persistent structural inefficiencies, including $165 million in certain litigation charges in the prior year that, while non-recurring, reveal ongoing vulnerabilities in quality management and cybersecurity that resurfaced in the Italian payback accrual adjustments ($7 million benefit in FY26 vs $20 million charge in FY25), suggesting unresolved regulatory exposures in key European markets that could recur and erode margins, and while management highlighted international growth, the U.S. segment showed only 1.5% organic revenue growth in both Q4 and FY26, indicating saturation in the core market where reimbursement pressures and competition from rivals like Tandem and Insulet are limiting pricing power, a dynamic not adequately addressed in the outlook that assumes continued expansion without addressing why U.S. growth remains stagnant despite new product launches.
The company's heavy reliance on Medtronic for critical infrastructure and support creates an underappreciated execution risk post-IPO, as MiniMed remains financially and operationally tethered to its former parent through intercompany debt repayment (using ~$538 million of IPO proceeds) and ongoing transition services, yet the earnings call and recent news avoided detailing the timeline, cost, or operational complexity of fully separating systems such as supply chain logistics, IT platforms, and after-sales service networks—critical functions that, if not smoothly transitioned, could disrupt product availability or increase operating expenses, and with Medtronic still owning 90.03% of shares post-IPO, there is a clear conflict of interest where strategic decisions may prioritize Medtronic's broader portfolio over MiniMed's standalone needs, a tension that surfaced in the cautious language around the "preferred path to complete the separation is a split-off" without commitment to timing or terms, leaving investors exposed to potential delays or unfavorable renegotiations that could strain MiniMed's balance sheet just as it scales new product launches.
While MiniMed celebrates the algorithm's robustness in glycemic outcomes, the company is ignoring the growing threat of sensor commoditization and competitive encroachment on its closed ecosystem, as the real-world evidence showing equivalent performance between Abbott's Instinct and Medtronic's Guardian 4 sensors undermines the proprietary advantage of its integrated stack, and with Abbott now pursuing dual glucose-ketone sensors through a non-exclusive framework (despite the current agreement's wording), there is a risk that MiniMed's algorithm becomes a licensed commodity rather than a defensible moat, especially if rivals like Dexcom or Roche develop interoperable AID systems that work with multiple sensors, a scenario MiniMed did not address when emphasizing the algorithm's central role, and without proprietary sensor IP or exclusive long-term supply contracts, the company's gross margins—already pressured by a 42.6% gross margin in Q4 FY26 (down from 42.8% in Q4 FY25 despite higher-margin CGM growth)—could face downward pressure as it negotiates with multiple sensor vendors, a vulnerability exacerbated by the Italian payback accrual history showing how regulatory shifts in key markets can abruptly alter profitability, a risk the market is not pricing in given the company's premium valuation multiples relative to pure-play diabetes peers.

Despite the positive top-line growth, MiniMed's fundamental profitability challenges are being underestimated by the market, as the company reported a net loss of $331 million for FY26—worsening from $213 million in FY25—driven not just by transient costs but by persistent structural inefficiencies, including $165 million in certain litigation charges in the prior year that, while non-recurring, reveal ongoing vulnerabilities in quality management and cybersecurity that resurfaced in the Italian payback accrual adjustments ($7 million benefit in FY26 vs $20 million charge in FY25), suggesting unresolved regulatory exposures in key European markets that could recur and erode margins, and while management highlighted international growth, the U.S. segment showed only 1.5% organic revenue growth in both Q4 and FY26, indicating saturation in the core market where reimbursement pressures and competition from rivals like Tandem and Insulet are limiting pricing power, a dynamic not adequately addressed in the outlook that assumes continued expansion without addressing why U.S. growth remains stagnant despite new product launches.
The company's heavy reliance on Medtronic for critical infrastructure and support creates an underappreciated execution risk post-IPO, as MiniMed remains financially and operationally tethered to its former parent through intercompany debt repayment (using ~$538 million of IPO proceeds) and ongoing transition services, yet the earnings call and recent news avoided detailing the timeline, cost, or operational complexity of fully separating systems such as supply chain logistics, IT platforms, and after-sales service networks—critical functions that, if not smoothly transitioned, could disrupt product availability or increase operating expenses, and with Medtronic still owning 90.03% of shares post-IPO, there is a clear conflict of interest where strategic decisions may prioritize Medtronic's broader portfolio over MiniMed's standalone needs, a tension that surfaced in the cautious language around the "preferred path to complete the separation is a split-off" without commitment to timing or terms, leaving investors exposed to potential delays or unfavorable renegotiations that could strain MiniMed's balance sheet just as it scales new product launches.
While MiniMed celebrates the algorithm's robustness in glycemic outcomes, the company is ignoring the growing threat of sensor commoditization and competitive encroachment on its closed ecosystem, as the real-world evidence showing equivalent performance between Abbott's Instinct and Medtronic's Guardian 4 sensors undermines the proprietary advantage of its integrated stack, and with Abbott now pursuing dual glucose-ketone sensors through a non-exclusive framework (despite the current agreement's wording), there is a risk that MiniMed's algorithm becomes a licensed commodity rather than a defensible moat, especially if rivals like Dexcom or Roche develop interoperable AID systems that work with multiple sensors, a scenario MiniMed did not address when emphasizing the algorithm's central role, and without proprietary sensor IP or exclusive long-term supply contracts, the company's gross margins—already pressured by a 42.6% gross margin in Q4 FY26 (down from 42.8% in Q4 FY25 despite higher-margin CGM growth)—could face downward pressure as it negotiates with multiple sensor vendors, a vulnerability exacerbated by the Italian payback accrual history showing how regulatory shifts in key markets can abruptly alter profitability, a risk the market is not pricing in given the company's premium valuation multiples relative to pure-play diabetes peers.

Peer Comparison

Companies in the Health Information Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VEEV	Veeva Systems Inc	29.34 Bn	31.16	8.84	-
2	BTSG	BrightSpring Health Services, Inc.	13.49 Bn	46.18	0.99	2.50 Bn
3	HQY	Healthequity, Inc.	7.96 Bn	34.51	5.95	0.94 Bn
4	TXG	10x Genomics, Inc.	6.17 Bn	-272.14	9.65	-
5	HNGE	Hinge Health, Inc.	6.02 Bn	-11.77	9.31	-
6	MMED	MiniMed Group, Inc.	4.19 Bn	-8.88	1.38	-
7	WAY	Waystar Holding Corp.	4.14 Bn	32.80	3.58	1.47 Bn
8	DOCS	Doximity, Inc.	3.82 Bn	19.51	5.93	-

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password